BioSpace News Archive

Exhibiting its latest developments in medical materials capabilities at Medical Design & Manufacturing West, through Feb. 7 at the Anaheim Convention Center, ProAmpac, a global leader in flexible packaging, invites participants to explore the company’s approach to collaborative innovation.

Confluent Medical’s High-Performance Nitinol Tubing Center of Excellence Offers Nitinol Component Manufacturers the Most Comprehensive and Highest-Performance Selection of Nitinol Tubing Ideally Suited for Implantable Devices Such as Transcatheter Heart Valves.

TAGNOS will demonstrate the power of IoT, AI / machine learning and mobile communication to optimize OR and ED patient flow and enterprise-wide asset tracking at HIMSS19 Booth 540

PSI 2020, a campaign committee in Oregon, has released scientific polling showing that Oregon voters are currently split on the Psilocybin Service Initiative of Oregon, a ballot initiative measure aiming to legalize access to psilocybin assisted therapy in 2020.

The Association of State and Territorial Health Officials (ASTHO) commends President Trump’s State of the Union pledge to end HIV transmission by 2030.

Brown & Toland Chairman of the Board, Neal Birnbaum, M.D. will be retiring from his position effective February 28, 2019 after 10 years of service as chair and nearly two decades of service to the company. Fabiola Cobarrubias, M.D., M.B.A., will assume the role as chair

Life of Purpose Addiction Treatment Centers, along with other state & local colleges/universities and treatment centers throughout the greater Philadelphia region, announced today they are hosting five free community opioid addiction panel discussion and book signing events with advocate and author of “American Fix,” Ryan Hampton, from February 11th through February 15th, 2019.

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock,

INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, today announced that the Company’s common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol “INMB”.

Morrison & Foerster, a leading global law firm, is pleased to announce that it has opened an office in Boston to further extend its market-leading technology and life sciences capabilities.